Differences in simulated liver concentrations of toxic coumarin metabolites in rats and different human populations evaluated through physiologically based biokinetic (PBBK) modeling.
暂无分享,去创建一个
Ans Punt | Ivonne M C M Rietjens | I. Rietjens | A. Punt | Marelle G Boersma | Maria Zaleska | M. Zaleska | M. Boersma
[1] C. Diehm,et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. , 2002, VASA. Zeitschrift fur Gefasskrankheiten.
[2] J. DeJongh,et al. A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans , 1997, Archives of Toxicology.
[3] Paul Tobback,et al. Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with Food (AFC) on a request from the Commission , 2008 .
[4] O Pelkonen,et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. , 1995, American journal of human genetics.
[5] M. Andersen,et al. Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.
[6] E. Becker,et al. Safety aspects of a coumarin-troxerutin combination regarding liver function in a double-blind placebo-controlled study. , 2003, International journal of clinical pharmacology and therapeutics.
[7] A. A. Nelson,et al. Food flavourings and compounds of related structure. II. Subacute and chronic toxicity. , 1967, Food and cosmetics toxicology.
[8] D. G. Walters,et al. Identification of o-hydroxyphenylacetaldehyde as a major metabolite of coumarin in rat hepatic microsomes. , 1992, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[9] J. Freudenstein,et al. Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin. , 2003, International journal of clinical pharmacology and therapeutics.
[10] J. Fry,et al. O-hydroxyphenylacetaldehyde: a major novel metabolite of coumarin formed by rat, gerbil and human liver microsomes. , 1991, Biochemical and biophysical research communications.
[11] D. G. Walters,et al. Sex and strain differences in mouse hepatic microsomal coumarin 7-hydroxylase activity. , 1994, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[12] P. Novotny,et al. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. , 1999, The New England journal of medicine.
[13] E. Casalino,et al. Rat liver glutathione S-transferase activity stimulation following acute cadmium or manganese intoxication. , 2004, Toxicology.
[14] J. A. Bond,et al. In vivo metabolism of butadiene by mice and rats: a comparison of physiological model predictions and experimental data. , 1994, Carcinogenesis.
[15] A. M. Api,et al. Comparative metabolism and kinetics of coumarin in mice and rats. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[16] G. Simon,et al. Effects of coumarin following perinatal and chronic exposure in Sprague-Dawley rats and CD-1 mice. , 1996, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[17] A. Parkinson,et al. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. , 1997, Archives of biochemistry and biophysics.
[18] M L Shuler,et al. Use of In Vitro Data for Construction of a Physiologically Based Pharmacokinetic Model for Naphthalene in Rats and Mice To Probe Species Differences , 1999, Biotechnology progress.
[19] D. G. Walters,et al. Metabolism of coumarin and 7-ethoxycoumarin by rat, mouse, guinea pig, cynomolgus monkey and human precision-cut liver slices. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.
[20] S. Born,et al. o-hydroxyphenylacetaldehyde is a hepatotoxic metabolite of coumarin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[21] George P Daston,et al. Metabolic detoxification determines species differences in coumarin-induced hepatotoxicity. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[22] J. Idle,et al. A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. , 1997, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[23] D. G. Walters,et al. Metabolism of [3-14C] coumarin by human liver microsomes. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.
[24] M. Delp,et al. Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.
[25] M. Metzler,et al. Possible role of oxygen radicals in cell transformation by diethylstilbestrol and related compounds. , 1986, Carcinogenesis.
[26] D. Lewis,et al. Studies on the mechanism of coumarin-induced toxicity in rat hepatocytes: comparison with dihydrocoumarin and other coumarin metabolites. , 1989, Toxicology and Applied Pharmacology.
[27] B. Lake,et al. Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. , 1999, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[28] S. Born,et al. Identification of the cytochromes P450 that catalyze coumarin 3,4-epoxidation and 3-hydroxylation. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[29] Joseph P. Balthasar,et al. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[30] J. Idle,et al. Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6 , 1998, European Journal of Clinical Pharmacology.
[31] S. Born,et al. Synthesis and reactivity of coumarin 3,4-epoxide. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[32] Ginette Truchon,et al. Impact of human variability on the biological monitoring of exposure to toluene: I. Physiologically based toxicokinetic modelling. , 2002, Toxicology letters.
[33] M E Andersen,et al. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. , 1984, Toxicology and applied pharmacology.
[34] M. Elizalde,et al. Activity of glutathione-S-transferase in rat liver and kidneys after administration of lead or cadmium , 2005, Archives of Toxicology.
[35] S. Born,et al. In vitro kinetics of coumarin 3,4-epoxidation: application to species differences in toxicity and carcinogenicity. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.
[36] M. Smyth,et al. Interspecies differences in coumarin metabolism in liver microsomes examined by capillary electrophoresis. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.
[37] S P Felter,et al. A safety assessment of coumarin taking into account species-specificity of toxicokinetics. , 2006, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.